Global Bronchodilators Market is Expected to Foresee Significant Growth. North America to lead the growth!
- Vikas Kumar
- January 12, 2023
- HEALTHCARE, NEWS
- Bronchodilators Market, Bronchodilators Market Analysis, Bronchodilators Market Growth, Bronchodilators Market Share, Bronchodilators Market Size, Bronchodilators Market Trend
- 0 Comments
The global bronchodilators market is expected to register a CAGR of around ~5% over the period of 2021-2027. Bronchodilators are drugs that open up (dilate) the breathing passages by relaxing the bronchial smooth muscle. They make breathing easier for people with asthma or other lung conditions. Thus, the increase in the number of patients with respiratory disorders, and the treatment of various diseases such as asthma, chronic obstructive pulmonary disease, and others. The geriatric population is more vulnerable to respiratory disorders such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, as per the data published by the Centers for Disease Control and Prevention (CDC), in 2019, around 4,069,278 Americans aged above 65 years were living with asthma. Since bronchodilators play a vital role in maintaining optimal airflow within the lungs of these patients, this is likely to boost the demand for bronchodilators in near future. Moreover, the development of advanced bronchodilators by major companies and the diagnostics industry owing to the presence of well-established market players and frequent product launches in the region. For instance, in July 2020, EVA Pharma launched ‘Inhalex’, the first Egyptian medication for COPD with a 24-hour lasting effect. This product launch is projected to reduce the cost of the treatment of COPD patients to half.
For a detailed analysis of the global Bronchodilators market browse through – https://univdatos.com/report/bronchodilators-market/
Based on drug type, the market is categorized into beta-adrenergic bronchodilators, anticholinergic bronchodilators, phosphodiesterase inhibitors, combination drugs, and others. Among these, the anticholinergic bronchodilators are expected to witness the highest CAGR during the forecast period as it is available in both long-acting and short-acting forms. Anticholinergics act by inhibiting the effect of acetylcholine on airways and nasal passages. Furthermore, anticholinergics bronchodilators hamper cholinergic nerves’ effect and lead the muscles to relax and dilate the airways..
Based on the route of administration, the market is categorized into oral, injection, and inhaler. Among these, oral is expected to witness the highest CAGR during the forecast period. This is mainly due to oral medication come in a variety of forms, including liquids, tablets, and capsules. These oral drugs are given in high doses that are absorbed directly into the bloodstream and have relatively fewer side effects.
Request for Sample of the report browse through – https://univdatos.com/get-a-free-sample-form-php/?product_id=32402
For a better understanding of the market adoption of the bronchodilators industry, the market is analyzed based on its worldwide presence in the countries such as North America (US, Canada, Rest of North America); Europe (Germany, UK, France, Italy, Spain, and Rest of Europe); Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), and Rest of World. North America is expected to witness the highest CAGR during the forecast period on account of the growing number of various bronchodilators and medical treatment activities for various diseases in countries like the U.S. and Canada. The major factors such as favorable government initiatives, increased investments in research and development for technologically advanced bronchodilator systems and the rapid increase in lung diseases are propelling the growth of this market in the region. Furthermore, increasing government initiatives towards raising awareness regarding asthma, and chronic respiratory disorders among others increases research on the medical applications of bronchodilators. As per the Asthma and Allergy Foundation of America, around 25 million Americans have asthma. This equals to about 1 in 13 Americans, including 8 percent of adults and 7 percent of children in 2019.
Some of the major players operating in the market include Abbott Laboratories, AstraZeneca plc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., SANOFI, Teva Pharmaceutical Industries Ltd., Vectura Group Plc.
Global Bronchodilators Market Segmentation
Market Insight, by Indication
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Others
Market Insight, by Drug Type
- Beta-Adrenergic Bronchodilators
- Anticholinergic Bronchodilators
- Phosphodiesterase Inhibitor
- Combination Drugs
- Others
Market Insight, by Route of Administration
- Oral
- Injection
- Inhaler
Market Insight, by Region
- North America
- U.S.
- Canada
- Rest of North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- Rest of Asia-Pacific
- Rest of World
Top Company Profiles
- Abbott Laboratories
- AstraZeneca plc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline Plc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG.
- Pfizer Inc.
- SANOFI
- Teva Pharmaceutical Industries Ltd.
- Vectura Group Plc
